Search

Your search keyword '"Gal Yadid"' showing total 42 results
Start Over "Gal Yadid" Language english Database Gale General OneFile
42 results on '"Gal Yadid"'

1. Clearmind announces preclinical results for cocaine addiction treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary
Abstract

Clearmind Medicine announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from [...]

Published
2022

2. Clearmind announces pre-clinical results for cocaine addiction treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary
Abstract

Clearmind Medicine announced pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. The pre-clinical trial, led by Professor Gal Yadid and his team, from the [...]

Published
2022

3. Study Results from Bar Ilan University Provide New Insights into Obesity (Exercise Rescues Obesogenic-Related Genes in the Female Hypothalamic Arcuate Nucleus: A Potential Role of miR-211 Modulation)

Subjects
Brain -- Research, Gene expression -- Research, Genetic research, Genes -- Research, Physical fitness -- Research, Health, Bar-Ilan University
Abstract

2024 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on obesity is now available. According to news reporting [...]

Published
2024

6. SciSparc reports positive results from third part of Clearmind Medicine'spre-clinical study for cocaine addiction treatment

Subjects
Clinical trials -- Research, Cocaine -- Research, Drug abuse -- Research, Substance abuse -- Care and treatment, Pharmaceuticals and cosmetics industries
Abstract

SciSparc Ltd, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced additional positive pre-clinical results in ongoing series of [...]

Published
2023

7. Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating cocaine addiction There are no FDA-approved medications to [...]

Published
2023

8. Pluri Teams Up with Bar-Ilan University to Create PLX Cells for Cocaine Addiction Therapy

Subjects
Cocaine, Drug abuse -- Care and treatment, Substance abuse -- Care and treatment, General interest, News, opinion and commentary, Bar-Ilan University
Abstract

HAIFA: Pluri Inc., a biotech company, has signed an agreement with BIRAD-Research & Development Company Ltd., the commercial arm of Bar-Ilan University, to develop Pluri's PLX cells for the treatment [...]

Published
2023

9. Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) ('Clearmind' or the 'company'), a biotech company focused on discovery [...]

Published
2023

10. Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, General interest, News, opinion and commentary
Abstract

Tel Aviv, Israel / Vancouver, Canada: Clearmind Medicine Inc has issued the following news release: Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) ('Clearmind' or the 'company'), a biotech company [...]

Published
2023

11. 424B4: Clearmind Medicine Inc

Subjects
United States. Food and Drug Administration, Computershare Ltd., Depository Trust Co., Financial services industry, Financial services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- Filed pursuant to Rule 424(b)(4) Registration No. 333-273293 PROSPECTUS 6,775,000 Common Shares 725,000 Pre-Funded Warrants to Purchase 725,000 Common Shares 7,500,000 Common Warrants to Purchase [...]

Published
2023

12. SciSparc, Clearmind announces initial results for cocaine addiction treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Company earnings/profit, Business, News, opinion and commentary
Abstract

SciSparc announced that initial positive pre-clinical results for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine. Pursuant to SciSparc last announcement on June 2, 2022, [...]

Published
2022

13. 424B4: Clearmind Medicine Inc

Subjects
United States. Securities and Exchange Commission, United States. Food and Drug Administration, Computershare Ltd., Depository Trust Co., Financial services industry, Financial services industry, Business, general
Abstract

(EDGAR Online via COMTEX) -- Filed pursuant to Rule 424(b)(4) Registration No. 333-270859 PROSPECTUS 3,097,459 Common Shares Pre-Funded Warrants to Purchase 1,408,259 Common Shares Common Warrants to Purchase 4,505,718 Common [...]

Published
2023

14. Israeli Biotech Clearmind Medicine Announced Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Subjects
Major depressive disorder, Ketamine, Biotechnology, Biotechnology industry, General interest, News, opinion and commentary
Abstract

Tel Aviv: Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (Clearmind or the Company), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major [...]

Published
2023

16. Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Subjects
Major depressive disorder, Ketamine, Homeopathy -- Materia medica and therapeutics, Biotechnology, Biotechnology industry, Therapeutics, Banking, finance and accounting industries, Business
Abstract

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) ('Clearmind' or 'the Company'), a biotech company focused on [...]

Published
2023

17. SciSparc Announces Additional Positive Result from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Subjects
Clinical trials -- Research, Cocaine -- Research, Drug abuse -- Care and treatment -- Research, Substance abuse -- Care and treatment, General interest, News, opinion and commentary
Abstract

TEL AVIV: SciSparc Ltd. (Nasdaq: SPRC) ('Company' or 'SciSparc'), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced [...]

Published
2023

18. Israel-Based Clearmind Issues Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Subjects
Clinical trials -- Research, Cocaine -- Research, Drug abuse -- Research, Substance abuse -- Care and treatment, General interest, News, opinion and commentary
Abstract

Tel Aviv: Clearmind Medicine Inc., a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced additional positive pre-clinical results in its [...]

Published
2023

19. Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment

Subjects
Clinical trials, Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process Tel Aviv, [...]

Published
2023

20. SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Subjects
Clinical trials, Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of addiction without interrupting the natural reward process. TEL AVIV, Israel, [...]

Published
2023

21. SciSparc Ltd. Announced Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Company earnings/profit, Business, international
Abstract

TEL AVIV: SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the Company or SciSparc), today [...]

Published
2022

23. Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

VANCOUVER, Aug 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (PinkSheets:CMNDF),(Pinksheets:CMNDF),(CNSX:CMND.CN),(Frankfurt:CWY0), EQNX::TICKER_END The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI [...]

Published
2022

24. SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Company earnings/profit, Banking, finance and accounting industries, Business
Abstract

TEL AVIV, Israel, Aug 24, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:SPRC),(OtherOTC:CMNDF),(Boerse Frankfurt - Freiverkehr:CWY0),(CNSX:CMND.CN), EQNX::TICKER_END Results indicate significant decrease in cocaine craving in a sub-group that received the [...]

Published
2022

25. Clearmind Medicine Issues Positive Pre-Clinical Results for Cocaine Addiction Treatment

Subjects
Cocaine, Substance abuse -- Care and treatment, Business, international
Abstract

VANCOUVER: Clearmind Medicine Inc., a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced positive pre-clinical results for its treatment [...]

Published
2022

26. SciSparc Ltd. Reports Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc

Subjects
Cocaine, Drug abuse -- Drug therapy, Substance abuse -- Care and treatment, Company earnings/profit, Business, international
Abstract

TEL AVIV, Israel: SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced that initial positive pre-clinical results [...]

Published
2022

27. Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics

Subjects
Biogen Inc., Biological products industry, Multiple sclerosis, Mental health, Evidence-based medicine, Central nervous system, Stress (Psychology), General interest, News, opinion and commentary
Abstract

PALM BEACH: FinancialNewsMedia.com has issued the following news release: FinancialNewsMedia.com News Commentary - The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and [...]

Published
2022

28. SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc

Subjects
Cocaine, Drug abuse -- Drug therapy, Substance abuse -- Care and treatment, Company earnings/profit, Banking, finance and accounting industries, Business
Abstract

TEL AVIV, Israel, Jun 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:SPRC),(Other OTC:CMNDF),(Boerse Frankfurt - Freiverkehr:CWY0.F),(CNSX:CMND.CN), EQNX::TICKER_END SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the [...]

Published
2022

29. Clearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment

Subjects
Cocaine, Drug abuse, Substance abuse -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

VANCOUVER, June 07, Jun 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (PinkSheets:CMNDF),(Pinksheets:CMNDF),(CNSX:CMND.CN),(Frankfurt:CWY0), EQNX::TICKER_END The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine Clearmind [...]

Published
2022

30. Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics

Subjects
Mental health, Drug approval, Stress (Psychology) -- Care and treatment, Substance abuse -- Care and treatment, Business, News, opinion and commentary
Abstract

PALM BEACH, Fla., June 7, 2022 /PRNewswire/ -- https://www.financialnewsmedia.com/ News Commentary - The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are [...]

Published
2022

31. Research on Cell Therapy Detailed by Researchers at Bar-Ilan University (Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model)

Subjects
Biochemistry -- Research -- Reports, Nervous system diseases -- Research, Mental health -- Reports -- Research, Stem cells -- Reports -- Research, Cocaine -- Research, Biological products -- Health aspects, Drug abuse -- Research, Stem cell research -- Research -- Reports, Substance abuse -- Care and treatment, Health, Psychology and mental health, Bar-Ilan University -- Reports
Abstract

2022 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Research findings on cell therapy are discussed in a new report. According to [...]

Published
2022

33. New Anxiety Disorders Study Findings Reported from Bar Ilan University (Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder-An Animal Model and a Human Study)

Subjects
Baclofen -- Usage, Central nervous system depressants -- Usage, Substance abuse -- Usage, Health, Bar-Ilan University
Abstract

2022 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in anxiety disorders. According to news reporting originating from [...]

Published
2022

34. Study Data from Neuropharmacology Laboratory Provide New Insights into Testosterone Congeners (The Effect of Dehydroepiandrosterone Treatment on Neurogenesis, Astrogliosis and Long-Term Cocaine-Seeking Behavior in a Cocaine Self-Administration ...)

Subjects
Dehydroepiandrosterone, Cocaine, Testosterone, Health
Abstract

2021 DEC 17 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in testosterone congeners. According to news reporting from Ramat [...]

Published
2021

35. A new way to treat PTSD?

Subjects
Post-traumatic stress disorder, Epigenetic inheritance, Disease susceptibility, Health, Psychology and mental health
Abstract

2021 AUG 16 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Exposure to a traumatic experience can lead to post-traumatic stress disorder (PTSD), an [...]

Published
2021

36. Research on Depression Discussed by Researchers at Bar Ilan University (Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico-Striatal Loop That Are Implicated in Major Depression)

Subjects
Mental health -- Research, Depression, Mental -- Research, Health, Psychology and mental health, Bar-Ilan University
Abstract

2021 MAR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- A new study on depression is now available. According to news reporting from [...]

Published
2021

37. COCAINE ADDICTION, CRAVING AND RELAPSE

Subjects
Substance abuse treatment, Cocaine, Drug abuse, News, opinion and commentary, Bar-Ilan University, McGill University
Abstract

MONTREAL, Quebec, Canada -- The following information was released by McGill University: One of the major challenges of cocaine addiction is the high rate of relapse after periods of withdrawal [...]

Published
2015

38. Cocaine addiction, craving and relapse

Subjects
Substance abuse treatment, Cocaine, Drug abuse, Biological sciences, Health, Bar-Ilan University, McGill University
Abstract

By a News Reporter-Staff News Editor at Life Science Weekly -- One of the major challenges of cocaine addiction is the high rate of relapse after periods of withdrawal and [...]

Published
2015

39. Scientists at University of North Carolina Detail Research in Science

Subjects
Scientists -- Research, Universities and colleges -- North Carolina -- Research, Health, Psychology and mental health
Abstract

By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Investigators discuss new findings in Science. According to news reporting from Chapel Hill, North Carolina, by NewsRx journalists, [...]

Published
2013

40. Study links brain fatty acid levels to depression

Subjects
Brain, Arachidonic acid, Unsaturated fatty acids, Depression, Mental -- Research, Omega-3 fatty acids, Health, Science and technology, Research
Abstract

A group of researchers from Israel has discovered that rats exhibiting the signs of depression have increased levels of the omega-6 fatty acid, arachidonic acid, in their brains. The details [...]

Published
2005

41. Study links brain fatty acid levels to depression

Subjects
Brain, Arachidonic acid, Unsaturated fatty acids, Depression, Mental -- Research, Omega-3 fatty acids, Health, Research
Abstract

A group of researchers from Israel has discovered that rats exhibiting the signs of depression have increased levels of the omega-6 fatty acid, arachidonic acid, in their brains. The details [...]

Published
2005

42. Study links brain fatty acid levels to depression

Subjects
Depression, Mental -- Research, Brain, Arachidonic acid, Unsaturated fatty acids, Omega-3 fatty acids
Abstract

A group of researchers from Israel has discovered that rats exhibiting the signs of depression have increased levels of the omega-6 fatty acid, arachidonic acid, in their brains. The details [...]

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results